6+ hour, 6+ min ago  (154+ words) Cancer Network In this segment on early relapse multiple myeloma, Luciano Costa asks Muhamed Baljevic to contextualize the safety profile of BCMA-directed bispecific antibodies and how these considerations may influence use earlier in the disease course Baljevic discusses key toxicities,…...

1+ day, 2+ hour ago  (309+ words) Although not yet mature, overall survival data trended in favor of pirtobrutinib plus venetoclax/rituximab in the phase 3 BRUIN CLL-322 trial. The BRUIN CLL-322 trial fulfilled its primary end point by demonstrating a clinically meaningful and statistically significant PFS improvement per independent…...

14+ hour, 20+ min ago  (334+ words) Although ct DNA has limited utility in well-differentiated disease, it may have use in monitoring molecular residual disease in high-grade carcinomas. ct DNA in neuroendocrine cancers is not a mainstream approach, and the reason for that is, in small bowel…...

23+ hour, 11+ min ago  (271+ words) The FDA has granted FTD and cleared an IND application for daretabart, an anti-GD2 monoclonal antibody, for the treatment of high-risk neuroblastoma. The FDA has granted fast track designation to daretabart (hu1418 K322 A) for the treatment of patients with high-risk neuroblastoma, according…...

18+ hour, 8+ min ago  (248+ words) Roisin E. O'Cearbhaill, MD, discussed the MUC16 CD28 bispecific antibody REGN5668 in treating patients with recurrent ovarian or endometrial cancer. At the 2026 Society of Gynecologic Oncology Annual Meeting on Women's Cancer (SGO), Cancer Network" spoke with Roisin E. O'Cearbhaill, MD, about a poster she shared…...

20+ hour, 1+ min ago  (267+ words) The FDA has assigned a Prescription Drug User Fee Act date of October 10, 2026, for ifinatamab deruxtecan in extensive-stage small cell lung cancer. The FDA has granted priority review to a biologics license application (BLA) seeking approval for ifinatamab deruxtecan (I-DXd)…...

3+ day, 15+ hour ago  (326+ words) Cancer Network Treatment with peptide receptor radionuclide therapy (PRRT) did not result in the development of liver failure during the treatment of gastroenteropancreatic neuroendocrine tumors (GEP-NETs), particularly among patients with a very high liver tumor burden. Cancer Network" spoke with…...

3+ day, 20+ hour ago  (55+ words) Cancer Network Your AI-Trained Oncology Knowledge Connection! Highlighting Impactful ASCO GU Research Across Disease States FDA Accepts NDA for Imaging Agent TLX101-Px in Brain Cancer Cemiplimab Exhibits Long-Term Clinical Benefit in Advanced NSCLC Trial AI-Driven Risk Assessment is Transforming Breast…...

3+ day, 23+ hour ago  (377+ words) The SISTER trial was the first national randomized trial to demonstrate significantly improved outcomes for black women with endometrial cancer. Conversely, among 1: 1 peer sessions, discussion topics included managing adverse effects (AEs; 81%), completing treatment (57%), self-care (56%), nutrition (48%), exercise (41%), intro to treatment (22%), resources…...

4+ day, 12+ min ago  (145+ words) Immune checkpoint inhibition has not been explored robustly in lymphomas, despite displaying a profound impact on solid tumors. Jeff P. Sharman, MD, expressed that learning to manage immune-related adverse effects associated with these agents in traditional non-Hodgkin's lymphomas is paramount, expressing…...